Equities analysts forecast that FibroGen Inc (NASDAQ:FGEN) will report $55.05 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for FibroGen’s earnings, with estimates ranging from $28.84 million to $71.30 million. FibroGen posted sales of $42.51 million during the same quarter last year, which suggests a positive year over year growth rate of 29.5%. The firm is expected to announce its next quarterly earnings results on Tuesday, February 26th.
On average, analysts expect that FibroGen will report full year sales of $159.88 million for the current year, with estimates ranging from $133.74 million to $176.00 million. For the next financial year, analysts forecast that the firm will post sales of $232.33 million, with estimates ranging from $92.00 million to $365.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow FibroGen.
FibroGen (NASDAQ:FGEN) last released its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.15). The firm had revenue of $29.00 million during the quarter, compared to analysts’ expectations of $36.48 million. FibroGen had a negative net margin of 87.84% and a negative return on equity of 24.59%. The business’s revenue was down 28.6% compared to the same quarter last year.
A number of equities research analysts have recently weighed in on the company. ValuEngine cut FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. Leerink Swann set a $82.00 price target on FibroGen and gave the stock a “buy” rating in a report on Tuesday, September 11th. BidaskClub downgraded FibroGen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 9th. Zacks Investment Research raised FibroGen from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a report on Wednesday, October 17th. Finally, TheStreet downgraded FibroGen from a “c-” rating to a “d+” rating in a report on Wednesday, November 21st. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $72.25.
Shares of FibroGen stock opened at $37.97 on Friday. FibroGen has a one year low of $37.64 and a one year high of $68.55. The company has a market cap of $3.51 billion, a P/E ratio of -21.95 and a beta of 2.13. The company has a current ratio of 6.76, a quick ratio of 6.76 and a debt-to-equity ratio of 0.20.
In other FibroGen news, SVP Pat Cotroneo sold 1,011 shares of the firm’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $57.35, for a total value of $57,980.85. Following the transaction, the senior vice president now directly owns 220,422 shares of the company’s stock, valued at $12,641,201.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas B. Neff sold 39,636 shares of the firm’s stock in a transaction dated Thursday, September 20th. The shares were sold at an average price of $57.81, for a total value of $2,291,357.16. Following the sale, the chief executive officer now owns 2,744,734 shares of the company’s stock, valued at $158,673,072.54. The disclosure for this sale can be found here. In the last three months, insiders have sold 229,773 shares of company stock worth $11,424,203. Corporate insiders own 8.96% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. FMR LLC lifted its holdings in FibroGen by 23.8% in the second quarter. FMR LLC now owns 8,463,528 shares of the biopharmaceutical company’s stock worth $529,817,000 after acquiring an additional 1,624,749 shares during the last quarter. First Trust Advisors LP raised its holdings in FibroGen by 37.8% during the third quarter. First Trust Advisors LP now owns 1,652,213 shares of the biopharmaceutical company’s stock worth $100,372,000 after purchasing an additional 453,288 shares in the last quarter. PointState Capital LP raised its holdings in FibroGen by 92.0% during the second quarter. PointState Capital LP now owns 810,200 shares of the biopharmaceutical company’s stock worth $50,719,000 after purchasing an additional 388,300 shares in the last quarter. BlackRock Inc. raised its holdings in FibroGen by 4.6% during the second quarter. BlackRock Inc. now owns 6,182,657 shares of the biopharmaceutical company’s stock worth $387,037,000 after purchasing an additional 271,981 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. grew its position in FibroGen by 118.4% in the third quarter. Candriam Luxembourg S.C.A. now owns 410,900 shares of the biopharmaceutical company’s stock worth $24,962,000 after buying an additional 222,800 shares during the last quarter. Institutional investors and hedge funds own 64.86% of the company’s stock.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Read More: Leveraged Buyout (LBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.